5.3 Bronchodilators, Corticosteroids, Insulin & Oral Antidiabetic Agents

Bronchodilators, Corticosteroids, Insulin & Oral Antidiabetic Agents

Quick Answer: Beta-2 agonist bronchodilators can modestly raise exercise heart rate as a side effect — not a sign of a cardiac problem. Insulin and sulfonylureas carry the highest exercise-related hypoglycemia risk of any diabetes medication class, while SGLT2 inhibitors carry a distinct risk of euglycemic diabetic ketoacidosis during prolonged, intense exercise.

Bronchodilators

Beta-2 agonists are the backbone of bronchodilator therapy: short-acting agents (SABA — albuterol) are used for quick relief and, importantly, pre-exercise prophylaxis in patients prone to exercise-induced bronchospasm (EIB); long-acting agents (LABA — salmeterol, formoterol) are maintenance therapy, always paired with an inhaled corticosteroid in asthma. Because beta-2 agonists can cross-react with beta-1 receptors, especially at higher doses, they commonly cause tachycardia, palpitations, and tremor. A CEP should expect a modestly elevated exercise heart rate in a patient using these medications and recognize it as a known drug effect rather than mistaking it for deconditioning or an emerging cardiac event.

Anticholinergics/muscarinic antagonists (ipratropium, short-acting; tiotropium, long-acting) are a mainstay for COPD and have minimal cardiac stimulant effect — their main side effect is dry mouth. Confirm every EIB-prone patient carries a rescue inhaler at each session, and treat post-exertional cough, wheeze, or dyspnea as a possible sign of undertreated EIB worth reporting — not just being "out of shape." Timing also matters clinically: a SABA taken 15-30 minutes before exercise is generally more effective at preventing EIB symptoms than one taken after symptoms have already started, so confirming a patient's pre-exercise inhaler routine during the interview is a useful, low-effort safety check.

Corticosteroids

Inhaled corticosteroids (ICS — fluticasone, budesonide) are first-line controller therapy for asthma, frequently combined with a LABA. Systemic absorption is low but not zero: long-term daily ICS use has been associated in observational data with some hyperglycemia risk and myopathy symptoms, so it should not be treated as entirely risk-free. Oral/systemic corticosteroids (prednisone), used for exacerbations or chronic inflammatory conditions, carry a substantially higher risk profile: hyperglycemia (which can transiently worsen glycemic control and interact with insulin dosing in diabetic patients), corticosteroid myopathy (proximal muscle weakness, more common with higher-dose or long-term oral use), fluid retention, elevated blood pressure, increased infection risk, and reduced bone density. A patient on a burst or chronic course of oral steroids may show transient hyperglycemia and reduced tolerance for resistance training — this calls for closer monitoring, not the assumption that a steroid course changes nothing.

Insulin & Sulfonylureas: The Hypoglycemia Risk

Insulin (all formulations) and sulfonylureas (glipizide, glyburide, glimepiride) or meglitinides carry the highest exercise-related hypoglycemia risk of any diabetes medication class. Exercise independently increases insulin sensitivity and non-insulin-mediated glucose uptake into muscle, compounding the medication's glucose-lowering effect — sometimes for hours after the session ends. Current ADA Standards of Care guidance calls for checking blood glucose before, during (for longer sessions), and after exercise in patients on these agents, keeping fast-acting carbohydrate available, and considering a pre-exercise snack when glucose is low-normal or insulin action is near its peak. Injecting insulin into a limb about to be heavily exercised can also speed absorption and should be avoided. Recognize hypoglycemia symptoms (shakiness, sweating, confusion, irritability) — and remember from earlier in this chapter that a concurrent beta-blocker can blunt the adrenergic warning signs, making hypoglycemia harder to catch early in these patients.

Metformin, GLP-1 Agonists & SGLT2 Inhibitors

Metformin carries low hypoglycemia risk when used alone; its rare but serious risk is lactic acidosis, with caution warranted in renal impairment or dehydration — relevant after prolonged, intense exercise or in heat. GLP-1 receptor agonists (semaglutide, liraglutide) also carry low hypoglycemia risk alone, though GI side effects (nausea) can affect exercise tolerance or hydration status. SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) carry low hypoglycemia risk alone but a distinct risk of euglycemic diabetic ketoacidosis — ketoacidosis with a normal or only mildly elevated glucose reading that can delay recognition. This risk rises specifically with prolonged or intense exercise (e.g., endurance events), dehydration, low-carbohydrate intake, or illness. Counsel patients on SGLT2 inhibitors on adequate hydration and on recognizing DKA symptoms (nausea, vomiting, abdominal pain, fatigue) even when a glucose check looks reassuring.

Medication Class vs. Exercise-Relevant Risk